Agios Pharmaceuticals, Inc. (AGIO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 11:19AM EDT. Market open.
| Previous close | 34.58 |
| Open | 34.90 |
| Bid | 25.23 x 200 |
| Ask | 43.18 x 200 |
| Day's range | 33.63 - 35.40 |
| 52-week range | 19.80 - 35.50 |
| Volume | |
| Avg. volume | 762,693 |
| Market cap | 1.958B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Agios’ First Quarter 2024 Conference Call. [Operator Instructions] Please be advised that […]
- Simply Wall St.
Agios Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Agios Pharmaceuticals ( NASDAQ:AGIO ) First Quarter 2024 Results Key Financial Results Revenue: US$8.19m (up 46% from...
- GuruFocus.com
Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Agios Pharmaceuticals showcases a strong Q1 with significant progress in clinical trials and a solid cash reserve, setting the stage for future growth.
© 2024 Yahoo. All rights reserved.